Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ArthroCare Restatement Will Cut Up To $37 Million From ’06-’08 Sales Reports

This article was originally published in The Gray Sheet

Executive Summary

Radiofrequency surgical instrument maker ArthroCare plans to restate previously filed financial statements from 2006-2008 to account for improper recording of sales to certain entities, resulting in a $26 million-$37 million reduction in previously recorded revenues

You may also be interested in...



ArthroCare CEO Resigns As Inquiry Into Accounting, Billing Practices Expands

Veteran health care exec and ArthroCare board member David Fitzgerald will step in as acting CEO of the embattled surgical instrument maker now that former chief exec Michael Baker has resigned in the shadow of an accounting scandal and government investigations

ArthroCare CEO Resigns As Inquiry Into Accounting, Billing Practices Expands

Veteran health care exec and ArthroCare board member David Fitzgerald will step in as acting CEO of the embattled surgical instrument maker now that former chief exec Michael Baker has resigned in the shadow of an accounting scandal and government investigations

ArthroCare Expands Accounting Inquiry To All Divisions Dating Back To 2000

Troubled surgical instrument maker ArthroCare will expand the scope of a previously planned restatement of financial results to encompass all three of its business units for the past eight years to account for improper recording of sales to certain entities

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026368

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel